Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Roberto Passera et al.|Journal of Clinical Oncology|2010Cited by 167
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristicsDaniela Massi, Mario Mandalà, Valentina Audrito et al.|Annals of Oncology|2014Cited by 146